Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)

Cerus Corporation (NASDAQ:CERS) and a pharmaceutical unit of Nipro Corporation announced a collaboration agreement. The collaboration will lead to the development of efficient and easy-to-use disposable kit for red cells. The project will benefit from the proprietary technology of Nipro towards the creation a red cell disposable kit that suits the needs of small and large blood centers. Cerus Corporation (NASDAQ:CERS) stock performance was 7.55% … Continue reading Biotech Gainers: Cerus Corporation (NASDAQ:CERS), Omeros Corporation (NASDAQ:OMER), Durata Therapeutics Inc (NASDAQ:DRTX), Aastrom Biosciences Inc (NASDAQ:ASTM)

Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.06% percent to $ 4.15 yesterday on volume of 319,314 shares. The intra-day range of the stock was … Continue reading Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

Capstone Therapeutics Corp. (OTCMKTS:CAPS) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), today will hold a conference call and webcast to provide an operating update, discuss the start of AEM-28 Phase 1 clinical studies and report financial results for the fiscal year 2013. Capstone Therapeutics Corp. (OTCMKTS:CAPS) stock performance was 4.00% in last session and finished the day at $0.260. Traded volume was 57,580.00million … Continue reading Biotech Unusual Volume: Capstone Therapeutics (OTCMKTS:CAPS), Xencor (NASDAQ:XNCR), Durata Therapeutics (NASDAQ:DRTX), Clovis Oncology (NASDAQ:CLVS)

FB Nasdaq FB Facebook

Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

Sinovac Biotech Ltd (NASDAQ:SVA) a leading biopharmaceutical company in China has reported its fourth quarter and full year unaudited results for the period ending December 31, 2013. Sinovac Biotech Ltd. (NASDAQ:SVA) stock performance was 17.13% in last session and finished the day at $8.07. Traded volume was 4,876,818 million shares in the last session and the average volume of the stock remained 342.45 million shares. … Continue reading Biotech New Highs: Sinovac Biotech (NASDAQ:SVA), Neuralstem (NYSEMKT:CUR), Durata Therapeutics Inc (NASDAQ:DRTX), Recro Pharma (NASDAQ:REPH)

FB Nasdaq FB Facebook

Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance … Continue reading Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 2.14% in last session and finished the day at $27.16. Traded volume was 61,391.00 shares in the last session and the average volume of the stock remained 27,510.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. … Continue reading Biotech New Highs: BioSpecifics Technologies (NASDAQ:BSTC), Five Prime Therapeutics (NASDAQ:FPRX), IGI Laboratories (NYSEMKT:IG), Durata Therapeutics (NASDAQ:DRTX)